Log In
info@corena.com.tr
+90 (312) 236 43 35
Ümit Mahallesi Töyko Villaları, 2545. Sk. No:14, 06810 Çankaya/Ankara
.svg)
PRESS
CENTER
You can access up-to-date news about Corena and our blog posts containing new developments in the pharmaceutical field.
News
June 22, 2023
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline results from its randomized, double-masked, place..
May 24, 2023
Y-mAbs’ Danyelza injection receives marketing approval in Brazil
Danyelza will be given three times in a week to patients and the dosage will be repeated every four weeks.
Y-mAbs Therapeutics has rec..
Sep 26, 2022
Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focus..
May 23, 2022
Pharmacist Medication Insights: Ibalizumab (Trogarzo) for HIV
In March 2018, the FDA approved ibalizumab-uiyk (Trogarzo, Theratechnologies), an injectable CD4-directed post-attachment HIV-1 inhibitor, indicate..